论文部分内容阅读
目的观察缬沙坦联合川芎嗪治疗早期糖尿病肾病(DN)的临床疗效。方法选择符合早期糖尿病肾病诊断标准的患者85例,随机分为治疗组43例和对照组42例,两组患者均予控制血糖治疗,使患者血糖控制达标。治疗组在此基础上加用给予缬沙坦80mg,每日1次,口服,磷酸川芎嗪片100 mg,口服,每日3次,共8周。结果治疗后患者的平均动脉压、尿微量白蛋白排泄率显著下降,与治疗前及对照组比较有显著性意义(P<0.01),而血肌酐、血尿素氮、血钾无明显差别(P>0.05)。对照组治疗前、后患者的平均动脉压、尿微量白蛋白排泄率差别无显著性意义(P>0.05)。结论缬沙坦联合川芎嗪治疗早期糖尿病肾病,具有降低血压作用,可明显降低尿微量白蛋白,对肾功能具有保护作用,能延缓肾损害进展。且无明显不良反应,患者依从性高。
Objective To observe the clinical efficacy of valsartan and ligustrazine in the treatment of early diabetic nephropathy (DN). Methods A total of 85 patients with diagnostic criteria of early diabetic nephropathy were randomly divided into treatment group (n = 43) and control group (n = 42). Patients in both groups were given glycemic control and blood glucose control was achieved. On the basis of the treatment group, the treatment group was given valsartan 80mg once daily orally and ligustrazine phosphate tablets 100mg orally three times a day for 8 weeks. Results The mean arterial pressure and urinary albumin excretion rate of patients after treatment were significantly lower than those before treatment and control group (P <0.01), while serum creatinine, blood urea nitrogen and serum potassium had no significant difference (P > 0.05). The mean arterial pressure and urinary albumin excretion rate in the control group before and after treatment had no significant difference (P> 0.05). Conclusion Valsartan and ligustrazine treatment of early diabetic nephropathy, with lower blood pressure, can significantly reduce urinary albumin, renal function has a protective effect, can delay the progression of renal damage. And no obvious adverse reactions, patients with high compliance.